Evidence map›Paper›PMID 29257918›Full record

ArticleSLAS discovery : advancing life sciences R & D2018

Discovery of Selective Cannabinoid CB

Lisa M Ogawa, Neil T Burford, Yu-Hsien Liao, Caitlin E Scott, Ashley M Hine, Craig Dowling, Jefferson Chin, Mike Power, Edward J Hunnicutt, Victoria L Emerick and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Molecules (Basel, Switzerland) · 2022
    Article
  3. Characterization of Subtype Selective Cannabinoid CBPharmaceuticals (Basel, Switzerland) · 2021
    Article
  4. Article
  5. Review
  6. Identification and biochemical analyses of selective CBEuropean journal of pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Lisa M Ogawa1 Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA.
Neil T Burford2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Yu-Hsien Liao3 Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Caitlin E Scott3 Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Ashley M Hine3 Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Craig Dowling2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Jefferson Chin2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Mike Power2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Edward J Hunnicutt2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Victoria L Emerick2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Martyn Banks2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Litao Zhang2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Samuel W Gerritz2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Andrew Alt2 Bristol-Myers Squibb, Research and Development, Wallingford, CT, USA.
Debra A Kendall3 Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Bristol-Myers Squibb (United States) · USUniversity of Connecticut · USYale University · US

Funding

Skill Development for Diverse Scientific Careers: A New Course Predoctoral Program in Cellular and Molecular BiologyT32GM007223 · NIGMS · YALE UNIVERSITY · PI BASERGA, SUSAN J · 1985 to 2019
$31.0M
Determinants of the Cannabinoid Receptor Life CycleR01DA020763 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KENDALL, DEBRA A · 2007 to 2011
$1.5M
NIDA NIH HHS R01 DA020763NIGMS NIH HHS T32 GM007223
6 · The paper itself

Abstract

The endocannabinoid system (ECS) plays a diverse role in human physiology ranging from the regulation of mood and appetite to immune modulation and the response to pain. Drug development that targets the cannabinoid receptors (CB

Indexed as

AnimalsCannabinoid Receptor AgonistsCHO CellsCricetulusHEK293 CellsHigh-Throughput Screening AssaysHumansPainReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Cannabinoid Receptor AgonistsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2cAMPCB2high-throughput screeningreceptor binding

Identifiers

PMID29257918
PMCPMC6219460
OpenAlexW2776345311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.